Several ErbB-targeted inhibitors are currently in use, including trastuzumab (Herceptin) for metastatic breast cancer, cetuximab for metastatic colorectal cancer (CRC) and head and neck cancer, and panitumumab for metastatic CRC (Zhang et al. 2007). This evidence concerns the gene EGFR and colorectal carcinoma.